InMed Pharmaceuticals
About: InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Employees: 13
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
122% more capital invested
Capital invested by funds: $117K [Q2] → $259K (+$142K) [Q3]
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
7.54% more ownership
Funds ownership: 5.27% [Q2] → 12.8% (+7.54%) [Q3]
7% more funds holding
Funds holding: 14 [Q2] → 15 (+1) [Q3]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for INM.